Evaluation of safety and immuno-efficacy of a next generation live attenuated yellow fever vaccine in cynomolgus macaques

36 male NHPs were randomized into groups of nine to receive subcutaneous injection in the deltoid muscle region of the upper arm with a single commercial dose of Stamaril (4 LogCCID50) or YF-VAX (6 LogCCID50), or 4 or 5 LogCCID50 vYF at WSL stage. Nine months after vaccination, NHPs along with six additional unvaccinated controls were challenged by a single sub-cutaneous injection of 3.0 LogCCID50 wild-type YFV Asibi strain in the scapula region. Blood samples were obtained before vaccination (baseline) and at various time points after vaccination, and before and after challenge. Whole blood RNA-seq to assess the genes involved in the immune responses to vaccination and to challenge with the wild type YFV Asibi.